Technical Analysis for VAL - Valirx Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Down | Flat |
| Historical VAL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.35% | |
| Narrow Range Bar | Range Contraction | -2.35% | |
| NR7 | Range Contraction | -2.35% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. | |
Get a Trading Assistant
Valirx Plc Description
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Engineering Pharmaceutical Biotechnology Medicine Clinic Pipe Analysis Disease Life Sciences Cancer Oncology Clinical Trial Biopharmaceutical Biomarker Drug Development Biomarkers Cancer Screening Chemical Pathology Companion Diagnostic Prostate Cancer Treatment Of Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|---|
| Feb 23 | Are Insiders Buying ValiRx plc (LON:VAL) Stock? |
| Indicator | Value |
|---|---|
| 52 Week High | 73.0 |
| 52 Week Low | 3.3 |
| Average Volume | 706,038 |
| 200-Day Moving Average | 20.84 |
| 50-Day Moving Average | 22.05 |
| 20-Day Moving Average | 21.64 |
| 10-Day Moving Average | 20.75 |
| Average True Range | 1.42 |
| ADX | 13.22 |
| +DI | 19.10 |
| -DI | 17.86 |
| Chandelier Exit (Long, 3 ATRs ) | 22.05 |
| Chandelier Exit (Short, 3 ATRs ) | 23.30 |
| Upper Bollinger Band | 23.90 |
| Lower Bollinger Band | 19.38 |
| Percent B (%b) | 0.3 |
| BandWidth | 20.90 |
| MACD Line | -0.35 |
| MACD Signal Line | -0.34 |
| MACD Histogram | -0.0123 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.10 | ||||
| Resistance 3 (R3) | 22.03 | 21.52 | 21.88 | ||
| Resistance 2 (R2) | 21.52 | 21.17 | 21.55 | 21.80 | |
| Resistance 1 (R1) | 21.13 | 20.96 | 21.20 | 21.20 | 21.72 |
| Pivot Point | 20.62 | 20.62 | 20.65 | 20.65 | 20.62 |
| Support 1 (S1) | 20.23 | 20.27 | 20.30 | 20.30 | 19.78 |
| Support 2 (S2) | 19.72 | 20.06 | 19.75 | 19.70 | |
| Support 3 (S3) | 19.33 | 19.72 | 19.63 | ||
| Support 4 (S4) | 19.40 |
